CYP2C9 gene and susceptibility to major depressive disorder

A. Llerena, R. Berecz, P. Dorado, A. P. González, E. M. Peñas-Lledó, A. De la Rubia

Research output: Contribution to journalArticle

22 Citations (Scopus)


Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allele-specific PCR. The CYP2C9*3 allele frequency was higher (P<0.01) among the patients suffering from major depression than in a population of 89 schizophrenic patients (odds ratio=3.3) and 138 healthy volunteers (odds ratio=2.8). The results suggest that CYP2C9 genetic polymorphism may be related to a major depressive disorder due to an alteration in endogenous metabolism, although a linkage between CYP2C9 and some other gene related to depression cannot be ruled out.

Original languageEnglish
Pages (from-to)300-302
Number of pages3
JournalPharmacogenomics Journal
Issue number5
Publication statusPublished - Nov 27 2003



  • CYP2C9 gene
  • Depression
  • Schizophrenia

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Llerena, A., Berecz, R., Dorado, P., González, A. P., Peñas-Lledó, E. M., & De la Rubia, A. (2003). CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics Journal, 3(5), 300-302.